Healthcare Professionals
Please log in for special information and services

As a privately owned company AOP Orphan is devoted to long-term commitment, high quality, and continuity. For a small number of very special diseases the company is the sole supplier of some key therapeutic agents throughout the world.

Founding

AOP Orphan was founded in 1996 by Dr. Rudolf Widmann with the aim of developing and providing therapy options for patients with rare diseases, and then introducing the therapy options first in Austria, the European core countries of AOP Orphan, and finally in the international market.

Dr. Rudolf Widmann member of governing board AOP Orphan International AG | Founder

“I worked for several years in large international pharmaceutical companies and observed that there were some therapy options for rare diseases, but they did not reach the large majority of the patients.”

Why did you found AOP Orphan?
“When founding AOP Orphan in 1996 my aim was to make targeted treatment available to the maximum number of patients with rare diseases. I realized that these patients are frequently left alone in their suffering. As an entrepreneur the complex environment of rare diseases was a great challenge, but also an opportunity to be successful in this niche.”

What role did AOP Orphan’s sense of entrepreneurial responsibility play in the founding of the company?
“Entrepreneurial responsibility is no additionally imposed obligation for AOP Orphan, but the attitude that played an indispensable role at the very time the company was founded. AOP Orphan’s objective to provide effective help for persons with rare diseases originated from this sense of responsibility and has made the company what it is today.“

Facts & Figures

As a European pioneer in the treatment of rare and special diseases, AOP Orphan is active in all five continents with its several years of expertise. Since the very start the company has been focused on the individual needs and treatments of patients suffering from rare or special diseases. Based on its research-centered approach, AOP Orphan has a profound understanding of special diseases. Therefore, the company has been able to position itself as an innovative front-runner in the development of effective therapies and drugs.

 

Madrid
headquarter
Headquarters in MADRID
From its office in Madrid, Spain, the company manages operations all over Spain and Portugal. 
7 TEAM members
AOP Orphan Spain is a team of more than 7  dedicated and agile specialists. 
7
members
3
areas of treatment
3 Areas of Treatment
As a specialist for rare and special diseases AOP Orphan investigatesproduces and markets innovative solutions in the treatment areas of HaematoOncologyCardiology & Pulmonologyand Intensive Care. 

Team

Marco Messina Managing Director of AOP Orphan in Spain

"Since our establishment, we have had a very clear mission: to transform the daily lives of people with these pathologies through a deep understanding of the mechanisms of the disease, the specific needs of patients and by working closely with the healthcare professionals involved in their treatment."

Uriel García Ibarz Medical Director of AOP Orphan in Spain

"Our aim is to respond to the individual needs of the patients and to offer them therapeutic options that contribute to improving their lives.”

Vision & Mission

The future

Thanks to our advancements in the field of therapies, an increasing number of patients survive their disease or are able to live with it for a longer period of time. In the next few decades, personalized medicine, individual treatment opportunities will emerge more and more as the standard in AOP Orphan’s therapy concepts as well.

Novel technologies such as next-generation sequencing (NGS) will play an equally crucial role as the increasing quantities of big data and conclusions derived from the daily lives of patients also beyond the strictly regulated conditions of clinical trials, e.g. real-world evidence.

Furthermore, the increasing health competence, health literacy of patients and their family members will also determine the future of pharma and health care sector.